What the blend contains
The components recorded on the KLOW Blend entry, exactly as listed. A component with its own PeptiDex entry links through to it.
Components at a glance
| Attribute | GHK-Cu | KPV | BPC-157 | TB-500 |
|---|---|---|---|---|
| Compound class | Copper-binding tripeptide | Alpha-MSH-derived tripeptide fragment | Synthetic pentadecapeptide | Actin-binding peptide fragment |
| Length (amino acids) | 3 amino acids | 3 amino acids | 15 amino acids | 7 amino acids |
| Molecular weight | 340.4 Da | 342.43 g/mol | 1419.5 Da | ~4921 Da (full-length thymosin beta-4); ~889 Da for the Ac-LKKTETQ fragment form |
| Half-life | Not documented | Not documented | <30 minutes (elimination, reported in rats/dogs) | ~2-3 hours (elimination); tissue effects reported to persist for days |
“Not documented” means the PeptiDex entry records no value for that field. Nothing here is estimated.
Each component in the research literature
The 4 compounds below are this blend's documented components. Each section is that compound's own library entry — its class, its mechanism as described in the research literature, and the contexts it is studied in.
GHK-Cu — Copper-binding tripeptide
A copper-binding tripeptide studied in dermal-research and tissue-remodeling contexts.
GHK has a high affinity for copper(II) and is understood to act partly as a copper-delivery molecule, facilitating copper transport relevant to enzymatic and remodeling processes. In cell and skin research it has been associated with signaling that influences extracellular-matrix remodeling, collagen and glycosaminoglycan synthesis, and antioxidant and gene-expression effects. Much of this work is from in-vitro and skin studies.
Studied in these research contexts
KPV — Alpha-MSH-derived tripeptide fragment
A C-terminal tripeptide of α-MSH studied in inflammation and tissue-repair research.
KPV is reported in preclinical studies to exert anti-inflammatory effects, and research has explored both melanocortin-receptor-dependent signaling and intracellular actions independent of classic MSH pigmentation activity. It has been studied for downregulation of pro-inflammatory signaling such as NF-kB-associated pathways in cell and animal models of colitis. These findings derive from in-vitro and rodent research.
Studied in these research contexts
BPC-157 — Synthetic pentadecapeptide
A 15-amino-acid synthetic peptide fragment studied for its purported role in tissue-repair research.
In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.
Studied in these research contexts
TB-500 — Actin-binding peptide fragment
A synthetic fragment of Thymosin Beta-4 frequently studied alongside BPC-157 in repair-related research.
Thymosin Beta-4 and its actin-binding fragment are studied for their ability to sequester G-actin and influence actin polymerization, which relates to cell migration. In preclinical models, this activity has been linked to cell migration, angiogenesis and tissue-repair processes. These mechanisms are drawn largely from animal and cell-culture research and are not established in controlled human trials for TB-500 itself.
Studied in these research contexts
Mechanistic descriptions are quoted from each compound's own entry and reflect published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds. Listing a research area is not a claim of efficacy or a therapeutic indication.
Why these are co-studied
Cross-referenced for research context — not a usage or combination recommendation. Each note below is the research-context rationale recorded on the compounds' own library entries; follow a card for the full side-by-side comparison.
Frequently asked questions
What is GHK-Cu?
GHK-Cu is a complex of the naturally occurring tripeptide GHK (glycyl-L-histidyl-L-lysine) with a copper(II) ion. The GHK sequence is a subfragment of the alpha-2 chain of type I collagen and is present in human plasma, where its level declines with age. It is studied primarily as a copper-delivery and skin-remodeling signal peptide.
What is GHK-Cu studied for?
In research and cosmetic-formulation literature it is studied for collagen and glycosaminoglycan synthesis in dermal fibroblasts, wound-model remodeling, and antioxidant/gene-modulating activity. It is characterized as a signaling peptide rather than a therapeutic drug, and is not FDA-approved for treating any condition.
What is KPV?
KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains much of the parent hormone's anti-inflammatory activity while lacking its pigment-stimulating (melanocortin) effects. It is studied as a small anti-inflammatory peptide rather than as an approved therapeutic.
What is KPV studied for?
Preclinical research examines KPV for anti-inflammatory effects, particularly in models of intestinal inflammation and colitis, as well as skin inflammation. It is reported to enter cells and inhibit NF-kB signaling and pro-inflammatory cytokine production, and it can be transported into intestinal cells via the PepT1 transporter. No human clinical trials have confirmed these effects.
How does BPC-157 differ from TB-500?
Both are studied for tissue repair but differ in origin and mechanism: BPC-157 is a 15-amino-acid gastric-derived peptide associated with angiogenesis and nitric-oxide pathways, while TB-500 relates to thymosin beta-4 and actin regulation and cell migration. They are frequently co-studied because their proposed mechanisms are viewed as complementary rather than overlapping.
What is BPC-157 and what class of peptide is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids derived from a partial sequence of a protein found in human gastric juice. It is studied in the research literature as a cytoprotective and tissue-repair agent, not as an approved drug. It has no established endogenous receptor and its mechanisms are still under active investigation.
How does TB-500 differ from BPC-157?
TB-500 works largely through actin regulation and cell migration and is dosed on the order of milligrams per week, whereas BPC-157 is a smaller gastric-derived pentadecapeptide dosed in micrograms and linked to nitric-oxide and angiogenic pathways. They are commonly co-studied as complementary repair agents rather than substitutes.
What is TB-500 and how does it relate to thymosin beta-4?
TB-500 is a research peptide associated with thymosin beta-4 (Tbeta4), a 43-amino-acid actin-binding regulatory peptide. The name TB-500 is used in the research-chemical market for both full-length thymosin beta-4 (MW ~4921 Da) and, in some references, the acetylated active fragment covering residues 17-23 (Ac-LKKTETQ). Buyers should check each vendor's COA, since what is shipped as 'TB-500' varies.
Answers are published on each compound's own PeptiDex entry. They describe individual compounds in research contexts; none of them describes using the compounds together.
Continue exploring
- Full KLOW Blend entry — blend-level summary, mechanism and reported research context
- All documented research blends
- Compare any two library entries side by side
- Reconstitution calculator
- Research Library hub